Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer? | Zendy

Fiona Mienko | Zendy; Balázs Halmos | Zendy; Haiying Cheng | Zendy

Open Access

Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?

Author(s) -

Fiona Mienko,

Balázs Halmos,

Haiying Cheng

Publication year - 2020

Publication title -

annals of translational medicine

Language(s) - English

Resource type - Journals

eISSN - 2305-5847

pISSN - 2305-5839

DOI - 10.21037/atm.2020.02.68

Subject(s) - pembrolizumab , medicine , lung cancer , oncology , pd l1 , cancer , immunotherapy

Department of Medical Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA Correspondence to: Haiying Cheng, MD. Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA. Email: hcheng@montefiore.org. Provenance and Peer Review: This article was commissioned and reviewed by the Section Editor Dr. Jianrong Zhang, MD, MPH (PhD Candidate, Centre for Cancer Research; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne; Victorian Comprehensive Cancer Centre, Victoria, Australia). Comment on: Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer 2019;135:188-95.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research